Boston Scientific is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. In January 2026, Boston Scientific announced it would acquire Penumbra in a ~$15 billion cash and stock deal expected to close by yearend. The company is pursuing aggressive M&A to expand its interventional medical device portfolio and strengthen market position in high-growth segments.
Cyborg Score Rationale
The company achieved 19.9% reported revenue growth and 15.8% organic growth in 2025. For 2026, the company estimates net sales growth of approximately 10.5 to 11.5 percent on a reported basis. Strong operational performance and strategic acquisitions demonstrate execution excellence, though integration risks exist with the large Penumbra deal.
Top Insights
Q4 2025 net sales grew 15.9% reported and 12.7% organically.
Penumbra acquisition ($15 billion) announced January 2026 to expand neurovascular and oncology portfolios.
Pulsed field ablation market expected to grow in midteens in 2026.
2026 adjusted EPS guidance of $3.43-$3.49.
Named Competitors
Medtronic — Diversified medical device leader in cardiac, neuromodulation, and surgical solutions
Stryker — Medical technology company focused on orthopedic implants and surgical equipment
Johnson & Johnson Cardiovascular — Integrated healthcare conglomerate with cardiovascular device portfolio